Mark Koznarek Summary
“Stuck between a rock and a hard place”
Many multinational pharmaceutical companies operating in China stand accused of using bribery and other “commissions” to boost sales. GlaxoSmithKline alone is alleged to have paid about $500mm in bribes, and many other companies also stand accused.
This is only the latest of scandals and fines to plague the
pharmaceutical industry. For instance, the US has imposed over $30bil of fines, over the last two decades, for overpricing and illegal marketing.
Yet, the use of “commissions” in the China healthcare market is widespread, and many feel these “commissions” are a necessary part of doing business here, considering the low salaries of doctors.
These investigations are likely to lead to fines in China and perhaps elsewhere. More importantly, slower profit growth in
China is likely, as the scrutiny leads to higher costs of compliance, pricing pressures and slower sales growth. But the substantial long-term opportunities in the China market suggest the industry will “roll with the punches” and pay this price for continued market access.
163 words.
热门文档